Geode Capital Management LLC Purchases 142,201 Shares of Natera, Inc. (NASDAQ:NTRA)

Geode Capital Management LLC boosted its holdings in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 6.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,232,681 shares of the medical research company's stock after buying an additional 142,201 shares during the period. Geode Capital Management LLC owned approximately 1.69% of Natera worth $355,809,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the business. Captrust Financial Advisors lifted its position in Natera by 108.7% in the 3rd quarter. Captrust Financial Advisors now owns 5,689 shares of the medical research company's stock valued at $722,000 after acquiring an additional 2,963 shares in the last quarter. Paloma Partners Management Co purchased a new position in shares of Natera during the third quarter valued at approximately $238,000. Benjamin Edwards Inc. grew its holdings in Natera by 15,167.3% during the third quarter. Benjamin Edwards Inc. now owns 7,481 shares of the medical research company's stock worth $950,000 after buying an additional 7,432 shares in the last quarter. HighTower Advisors LLC raised its position in Natera by 2.4% in the 3rd quarter. HighTower Advisors LLC now owns 10,319 shares of the medical research company's stock valued at $1,309,000 after buying an additional 245 shares during the last quarter. Finally, Two Sigma Advisers LP lifted its stake in Natera by 39.9% during the 3rd quarter. Two Sigma Advisers LP now owns 315,300 shares of the medical research company's stock valued at $40,027,000 after acquiring an additional 89,900 shares in the last quarter. 99.90% of the stock is owned by institutional investors.

Remove Ads

Analyst Upgrades and Downgrades

NTRA has been the subject of several analyst reports. Guggenheim increased their target price on shares of Natera from $170.00 to $200.00 and gave the company a "buy" rating in a report on Friday, January 17th. Robert W. Baird lifted their target price on shares of Natera from $183.00 to $188.00 and gave the stock an "outperform" rating in a research report on Friday, February 28th. Royal Bank of Canada initiated coverage on Natera in a report on Thursday, March 13th. They issued an "outperform" rating and a $251.00 target price for the company. Piper Sandler lifted their price target on Natera from $200.00 to $205.00 and gave the stock an "overweight" rating in a report on Tuesday, March 4th. Finally, Barclays reduced their price objective on Natera from $200.00 to $160.00 and set an "overweight" rating for the company in a research note on Thursday. One analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $175.76.

Insider Transactions at Natera

In other news, CEO Steven Leonard Chapman sold 78,553 shares of the business's stock in a transaction that occurred on Wednesday, January 22nd. The stock was sold at an average price of $164.97, for a total value of $12,958,888.41. Following the sale, the chief executive officer now directly owns 267,629 shares of the company's stock, valued at $44,150,756.13. The trade was a 22.69 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Solomon Moshkevich sold 3,000 shares of the business's stock in a transaction on Tuesday, April 1st. The stock was sold at an average price of $140.48, for a total value of $421,440.00. Following the completion of the sale, the insider now directly owns 141,782 shares in the company, valued at $19,917,535.36. This trade represents a 2.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 325,922 shares of company stock valued at $51,603,664. Company insiders own 7.60% of the company's stock.

Natera Trading Down 8.2 %

Shares of NASDAQ NTRA traded down $12.39 during mid-day trading on Thursday, hitting $139.58. The stock had a trading volume of 586,868 shares, compared to its average volume of 1,387,391. The firm has a market cap of $18.87 billion, a P/E ratio of -79.25 and a beta of 1.80. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. The business has a 50 day moving average price of $153.85 and a two-hundred day moving average price of $151.75. Natera, Inc. has a 1 year low of $83.13 and a 1 year high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last posted its earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, topping analysts' consensus estimates of ($0.42) by $0.01. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The company had revenue of $476.10 million during the quarter, compared to analyst estimates of $447.91 million. On average, equities analysts anticipate that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.